Physician profile
Mark J Janicki
NPI 1588661409
$573,348.25
in general payments reported to CMS, 2019-2025
71 companies · $91K in 2025
The $91K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172K · 2020: $38K · 2021: $56K · 2022: $82K · 2023: $78K · 2024: $57K · 2025: $91K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $185K · Consulting Fee: $17K · Food and Beverage: $16K · Travel and Lodging: $6,136 · Education: $490 · Honoraria: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $185,494.50 |
| Consulting Fee | $16,800.00 |
| Food and Beverage | $16,452.14 |
| Travel and Lodging | $6,136.29 |
| Education | $489.93 |
| Honoraria | $450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $253,433.34 | 2019-2025 | Mavenclad, Mavenclad |
| Genzyme Corporation | $140,597.12 | 2019-2025 | |
| Biogen, INC. | $41,635.40 | 2019-2025 | Vumerity, Tysabri |
| Alexion Pharmaceuticals, INC. | $36,328.63 | 2019-2025 | Soliris, Ultomiris |
| Vanda Pharmaceuticals INC. | $28,546.37 | 2024-2025 | Ponvory |
| Janssen Pharmaceuticals, INC | $16,139.59 | 2021-2022 | |
| Celgene Corporation | $12,945.53 | 2020-2025 | Zeposia |
| Genentech USA, INC. | $11,468.20 | 2019-2024 | Ocrevus, Enspryng |
| Novartis Pharmaceuticals Corporation | $9,626.89 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $4,371.70 | 2020-2025 | Zeposia |
| Abbvie INC. | $2,355.03 | 2019-2025 | |
| Ucb, INC. | $1,827.83 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Janssen Scientific Affairs, LLC | $1,320.00 | 2021 | |
| Amgen INC. | $1,236.09 | 2019-2025 | Uplizna, Aimovig |
| Horizon Therapeutics Plc | $1,125.69 | 2022-2023 | Uplizna |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Janicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.